NCT01054196View on ClinicalTrials.gov

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

October 31, 2021

Study Completion Date

December 31, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

lenalidomide

daily dose dependent on dose-escalation schedule

DRUG

melphalan

100 mg/m2 given Days -2 and -1

Trial Locations (1)

10065

Weill Cornell Medical College, New York

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER